Back to top
more

Fate Therapeutics (FATE)

(Real Time Quote from BATS)

$3.88 USD

3.88
223,850

+0.01 (0.26%)

Updated Apr 26, 2024 10:43 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.

Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.

Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know

Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.

Ekta Bagri headshot

Novartis (NVS) to Report Q1 Earnings: What to Expect?

Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.

What's in Store for Biogen (BIIB) This Earnings Season?

Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.

J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress

Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.

Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y

Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 21.05% and 97.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock?

Fate Therapeutics (FATE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Fate Therapeutics (FATE) Upgraded to Buy: Here's Why

Fate Therapeutics (FATE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Fate Therapeutics (FATE) Up 10.3% Since Last Earnings Report: Can It Continue?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Philips (PHG) Adds Smart Fit Coils to Boost Diagnostic Imaging

Philips (PHG) launches three MR Smart Fit coils, namely TorsoCardiac 1.5T, 1.5T shoulder and Knee 3.0T, enhancing flexibility, reducing patient setup time and improving image quality resolution.

Philips (PHG) Bolsters Diagnostic Imaging With New Launches

Philips (PHG) unveils an array of AI-enabled innovations at RSNA23 to enhance diagnostic imaging capabilities across healthcare providers.

Philips (PHG) Adds BlueSeal to its Diagnostic Imaging Portfolio

Philips (PHG) showcases BlueSeal MR Mobile to enhance diagnostic imaging capabilities across remote and rural communities.

FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y

FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.

Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 246.15% and 63.68%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength?

Mirum Pharmaceuticals, Inc. (MIRM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss

FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.